Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2010

View Archived Issues

Alnylam provides key goals for next 18 months

Pharmasset provides new data on HCV candidate PSI-7851

ERalphaS118-P a potential biomarker for breast cancer response to tamoxifen

Novo Nordisk commences phase I trial with long-acting oral GLP-1 analogue

Sciele Pharma changes company name to Shionogi Pharma

Isis adds new drug to treat hypertriglyceridemia to development pipeline

Amicus Therapeutics presents development progress with Amigal

InterMune provides update on 2010 development program for RG-7227

Sorrento enters antibody alliance for MRSA infections

Idenix reports updated information on three of its HCV programs

AnaptysBio and Roche sign agreement for development of novel antibody therapeutics

Pharmaxis acquires Topigen

Shionogi receives marketing approval for peramivir in Japan

Genaera to sell remaining proprietary assets

Spectrum completes enrollment in second phase III pivotal apaziquone trial

Eisai submits application for approval of additional indication of Tambocor in Japan

Genfit reports results from phase I safety study of GFT-505/simvastatin combination

siRNA-nanosome formulations inhibit HCV RNA replication in interferon-resistant replicon cells

Activated protein C analogues slow progression in ALS model

Top2alpha proteasomal degradation can be inhibited to enhance cancer treatment

Novel sulfonylureas in development for diabetes therapy at Concert Pharmaceuticals

Bristol-Myers Squibb presents novel hepatitis C virus inhibitors

Yakult Honsha discovers novel Plk-1 inhibitors as oncolytics

Novel peptides for the diagnosis of invasive brain cancer described by U.S. scientists

Actelion Pharmaceuticals discloses novel antibacterials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...